Transition from argatroban to oral anticoagulation with phenprocournon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

被引:51
作者
Harder, S
Graff, J
Klinkhardt, U
von Hentig, N
Walenga, JM
Watanabe, H
Osakabe, M
Breddin, HK
机构
[1] Univ Hosp Frankfurt, Pharmazentrum Frankfurt, Inst Clin Pharmacol, D-60590 Frankfurt, Germany
[2] Loyola Univ, Maywood, IL 60153 USA
[3] Mitsubishi Pharma Corp, Tokyo, Japan
[4] Int Inst Thrombosis & Vasc Dis, Frankfurt, Germany
关键词
argatroban; phenprocoumon; acenocoumarol; interaction;
D O I
10.1160/TH03-12-0794
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment with the direct thrombin inhibitor argatroban (ARG) is often followed by vitamin K-antagonist treatment (VKA). Phenprocoumon (PC) and acenocoumarol (AC) are frequently used in Europe. The standard monitoring test for VKA, prothrombin time (PT), is prolonged by direct thrombin inhibitors. Therefore the International Normalized Ratio (INR) obtained during combined treatment does not reflect the true effect of the VKA. A similar interference of the VKA on the activated partial thromboplastin time (aPTT), a monitoring assay for direct thrombin inhibitors, can occur. In 39 healthy volunteers the effect of ARG alone or combined with PC or AC on PT INR, aPTT, and Ecarin Clotting Time (ECT) was investigated. 6 groups each of 6-8 volunteers received a 5-hour infusion of either 1.0, 2.0 or 3.0 mug/kg/min ARG (days 1, 3,4 and 5) before initiation of either PC or AC (day 1) and during continued VKA dosing (target INR 2-3). A linear relationship (INRARG+VKA = intercept + slope * INR VKA alone) was observed between the INR measured "on" and "off " ARG. The slope depended on the argatroban dose and on the International Sensitivity Index (ISI) of the PT reagent, the steepest slope (i.e., the largest difference between INR (ARG+VKA) and INR (VKAalone)) was seen with the highest ARG dose and the PT reagent with an ISI of 2.13. There was a close correlation between plasma levels of ARG and aPTT or ECT Under VKA the ARG-aPTT relationship indicated an increased sensitivity of the aPTT to ARG,VKA treatment had no effect on the prolongation of the ECT induced by argatroban. In conclusion, ARG at doses up to 2 mug/kg/min can be discontinued at an INR of 4.0 on combined therapy with VKA, as this would correspond to an INR between 2.2 and 3.7 for the VKA. If it is necessary to monitor ARG in the critical transition period, the ECT which is not influenced byVKA can be used as an alternative to the aPTT.
引用
收藏
页码:1137 / 1145
页数:9
相关论文
共 21 条
[1]  
Chantarangkul V, 2003, HAEMATOLOGICA, V88, P547
[2]  
Chen J L, 2001, Heart Dis, V3, P189, DOI 10.1097/00132580-200105000-00009
[3]   Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects [J].
Eriksson, UG ;
Bredberg, U ;
Gislén, K ;
Johansson, LC ;
Frison, L ;
Ahnoff, M ;
Gustafsson, D .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (01) :35-43
[4]   Effects of PEG-Hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers [J].
Esslinger, HU ;
Köhne, S ;
Radziwon, P ;
Walenga, JM ;
Breddin, HK .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2003, 9 (01) :79-88
[5]   The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers [J].
Faaij, RA ;
van Griensven, JMT ;
Schoemaker, RC ;
Goggin, T ;
Guenzi, A ;
Kroon, JM ;
Burggraaf, J ;
Cohen, AF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) :25-29
[6]   Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients [J].
Faber, CG ;
Lodder, J ;
Kessels, F ;
Troost, J .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (01) :52-58
[7]   Monitoring of anticoagulant effects of direct thrombin inhibitors [J].
Fenyvesi, T ;
Jörg, I ;
Harenberg, J .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (04) :361-368
[8]  
Fenyvesi T, 2002, CLIN CHEM, V48, P1791
[9]   Methods for the monitoring of direct thrombin inhibitors [J].
Hafner, G ;
Roser, M ;
Nauck, M .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (05) :425-430
[10]   Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs - A review of small-molecule thrombin inhibitors [J].
Hauptmann, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (11) :751-758